Clinicopathologic characteristics of patients with ENKTL
| Characteristic . | n = 71 . |
|---|---|
| Age, median (range), y | 66 (6-100) |
| Sex, male/female, n (%) | 41 (58)/30 (42) |
| B symptoms, yes/no, n (%) | 21 (36)/37 (64) |
| LDH above the UNL, yes/no, n (%) | 38 (64)/21 (36) |
| Stage, n (%) | |
| I | 29 (49) |
| II | 12 (20) |
| III | 3 (5) |
| IV | 15 (25) |
| Nasal lesion, yes/no, n (%) | 45 (70)/19(30) |
| Regional LN involvement, yes/no, n (%) | 20 (33)/41 (67) |
| Distant LN involvement, yes/no, n (%) | 7 (11)/54 (89) |
| NKPI group, n (%) | |
| Group 1 | 10 (17) |
| Group 2 | 22 (38) |
| Group 3 | 10 (17) |
| Group 4 | 16 (28) |
| PINK risk, n (%) | |
| Low | 21 (36) |
| Intermediate | 27 (47) |
| High | 10 (17) |
| Treatment, n (%) | |
| AC-free CTX and/or RT | 45 (74) |
| Other CTX | 8 (13) |
| No (including BSC) | 8 (13) |
| Characteristic . | n = 71 . |
|---|---|
| Age, median (range), y | 66 (6-100) |
| Sex, male/female, n (%) | 41 (58)/30 (42) |
| B symptoms, yes/no, n (%) | 21 (36)/37 (64) |
| LDH above the UNL, yes/no, n (%) | 38 (64)/21 (36) |
| Stage, n (%) | |
| I | 29 (49) |
| II | 12 (20) |
| III | 3 (5) |
| IV | 15 (25) |
| Nasal lesion, yes/no, n (%) | 45 (70)/19(30) |
| Regional LN involvement, yes/no, n (%) | 20 (33)/41 (67) |
| Distant LN involvement, yes/no, n (%) | 7 (11)/54 (89) |
| NKPI group, n (%) | |
| Group 1 | 10 (17) |
| Group 2 | 22 (38) |
| Group 3 | 10 (17) |
| Group 4 | 16 (28) |
| PINK risk, n (%) | |
| Low | 21 (36) |
| Intermediate | 27 (47) |
| High | 10 (17) |
| Treatment, n (%) | |
| AC-free CTX and/or RT | 45 (74) |
| Other CTX | 8 (13) |
| No (including BSC) | 8 (13) |
AC, anthracycline; BSC, best supportive care; CTX, chemotherapy; LN, lymph node; RT, radiotherapy; UNL, upper normal limit.